Clinical trials: HPV-Associated Cervical Carcinoma
Head and Neck Cancer
DNA Analysis of Tumor Tissue Samples From Patients With Human Papilloma Virus-Associated Cancer of the Oropharynx
RATIONALE: Studying samples of tumor tissue in the laboratory from patients with cancer may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
- Trial name
- NCT00897988
- Testing
- gene expression analysis, mutation analysis, polyacrylamide gel electrophoresis
- Where
- 3 sites in United States
- Volunteers
- 40 people
- Sponsor
- Vanderbilt University Medical Center
CDKN2A-p16 Positive, HPV Positive Oropharyngeal Squamous Cell Carcinoma
Alpelisib in Treating Participants With Transorally Resectable HPV-Associated Stage I-IVA Oropharyngeal Cancer
This phase II trial studies how well alpelisib works in treating participants with human papillomavirus(HPV)-associated stage I-IVA head and neck cancer that can be removed by surgery.
- Conditions
- CDKN2A-p16 Positive, HPV Positive Oropharyngeal Squamous Cell Carcinoma, Stage I Oropharyngeal Squamous Cell Carcinoma AJCC V7, Stage II Oropharyngeal Squamous Cell Carcinoma AJCC V7
- Trial name
- NCT03601507
- Testing
- Alpelisib, Laboratory Biomarker Analysis, Pharmacodynamic Study
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- University of Arizona
Cancer of Cervix
Prevention and Control of Neoplasms Associated With HPV in High-risk Groups in Mexico City: The Condesa Study
Objective: To evaluate the effectiveness of a combined strategy of human papillomavirus virus (HPV) vaccination and high-risk HPV screening to reduce the occurrence of neoplasms in the anogenital region and oral cavity among men…
- Trial name
- CONDESA (NCT05149248)
- Testing
- Gardasil® [Quadrivalent Human Papillomavirus (Types 6,11,16,18) Recombinant vaccine], Two dose, Control group
- Where
- Mexico
- Volunteers
- 6,000 people, healthy volunteers welcome
- Sponsor
- Instituto Nacional de Salud Publica, Mexico
HPV Infection, HPV-Related Cervical Carcinoma
A Randomized, Blinded, Placebo-controlled Phase I Clinical Trial Evaluating the Safety and Preliminary Immunogenicity of a 11-valent Recombinant Human Papillomavirus Vaccine (Hansenulapolymorpha) in Chinese Women Aged 9-45 Years
A total of 90 Chinese women aged 9-45 years old were divided into three age groups: 27-45 years old, 18-26 years old, and 9-17 years old. The experimental group and the placebo group were randomly assigned in a ratio of 2:1.
- Trial name
- NCT04083196
- Testing
- 11-valent recombinant human papilloma virus vaccine (Hansenula polymorpha)
- Where
- China
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- National Vaccine and Serum Institute, China
HPV-Related Cervical Carcinoma
Effectiveness of Targeted Educational Interventions at Increasing HPV Vaccine Acceptability and Uptake
This study aims to assess the effectiveness of targeted educational interventions in increasing the acceptability and knowledge of the HPV vaccine among females ages 12 through 26.
- Trial name
- NCT03337269
- Testing
- Educational video, Educational handout, Control
- Where
- United States
- Volunteers
- 256 people, healthy volunteers welcome
- Sponsor
- University of Pennsylvania
Human Papillomavirus, Cervix Cancer
Prevention of HPV in the School Health Service
The last ten years sexually transmitted infections (STI) have substantially increased among adolescents. STI can lead to individual suffering and have a negative effect on the future reproductive health and also increase the need…
- Trial name
- NCT02280967
- Testing
- Education about HPV by school nurse
- Where
- Sweden
- Volunteers
- 832 people, healthy volunteers welcome
- Sponsor
- Uppsala University
Cervical Cancer, Vaginal Cancer
Peripheral Stem Cell Transplant, White Blood Cell Infusions, Chemotherapy, and Radiation Therapy in Treating Patients With Recurrent Metastatic Cervical or Vaginal Cancer
RATIONALE: Giving low doses of chemotherapy, such as fludarabine, and radiation therapy before a donor peripheral blood stem cell transplant helps stop the growth of cancer cells.
- Trial name
- NCT00005941
- Testing
- therapeutic allogeneic lymphocytes, cyclosporine, fludarabine phosphate
- Where
- United States
- Sponsor
- Fred Hutchinson Cancer Center
HPV, HPV-Related Cervical Carcinoma
STI Knowledge and HPV Vaccine Acceptance in Bamako, Mali in 2012
Although screening for pre-cancerous cervical lesions and human papilloma virus (HPV) vaccination are accepted and effective means to prevent cervical cancer, women in Mali have limited access to these interventions.
- Trial name
- NCT05767138
- Testing
- HPV Vaccine Acceptance Survey
- Volunteers
- 301 people, healthy volunteers welcome
- Sponsor
- Global Alliance to Immunize Against AIDS Vaccine Foundation